Novartis AG
Closed
154.58 -1.45
Overview
Share price change
24h
Min
154.74
Max
157.3
Income | 110M 3.3B |
|---|---|
Sales | 894M 14B |
P/E Sector Avg | 23.213 68.51 |
EPS | 2.41 |
Dividend yield | 3.04 |
Profit margin | 22.654 |
Employees | 75,267 |
EBITDA | 526M 5.9B |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +1.41% upside |
Dividend yield Sector Avg | 3.04% 2.29% |
|---|
Market Cap | 6.7B 292B |
|---|---|
Previous open | 156.03 |
Previous close | 154.58 |
Novartis AG Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Novartis AG Forecast
Price Target
By TipRanks
1.41% upside
12 Months Forecast
Average 159 USD 1.41%
High 180 USD
Low 139 USD
Based on 5 Wall Street analysts offering 12 month price targets forNovartis AG - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Novartis AG
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
